Preventive effect of naringin on isoproterenol-induced cardiotoxicity in Wistar rats: an in vivo and in vitro study.
This study was aimed to evaluate the preventive role of naringin on heart weight, blood glucose, total proteins, albumin/globulin (A/G) ratio, serum uric acid, serum iron, plasma iron binding capacity and membrane bound enzymes such as sodium potassium-dependent adenosine triphosphatase (Na(+)/K(+) ATPase), calcium-dependent adenosine triphosphatase (Ca(2+) ATPase) and magnesium-dependent adenosine triphosphatase (Mg(2+) ATPase) and glycoproteins such as hexose, hexosamine, fucose and sialic acid in isoproterenol (ISO)-induced myocardial infarction (MI) in rats and in vitro free radical scavenging assay. Male albino Wistar rats were pretreated with naringin (10, 20 and 40 mg/kg, respectively) for a period of 56 days. After the treatment period, ISO (85 mg/kg) was subcutaneously injected to rats at an interval of 24 h for 2 days. ISO-induced rats showed a significant (P<0.05) increase in the heart weight, blood glucose, serum uric acid, serum iron and a significant (P<0.05) decrease in the levels of total proteins, A/G ratio and iron binding capacity. A significant (P<0.05) decrease in the activity of Na(+)/K(+) ATPase and increase in the activities of Ca(2+) and Mg(2+) ATPase in the heart and a significant (P<0.05) increase in the levels of glycoproteins in serum and the heart were also observed in ISO-induced rats. Pretreatment with naringin for a period of 56 days exhibited a significant (P<0.05) effect and altered these biochemical parameters positively in ISO-induced rats. Naringin also scavenges 1,1-diphenyl-2-picrylhydrazyl (DPPH), 2,2'-azinobis-(3-ethyl-benzothiazoline-6-sulfonic acid) (ABTS) and nitric oxide (NO) radicals in vitro. Thus, our study shows that naringin has cardioprotective role in ISO-induced MI in rats.
Rajadurai
M
M
Department of Biochemistry and Biotechnology, Annamalai University, Annamalainagar-608002, Tamil Nadu, India.
Prince
P Stanely Mainzen
PS
D000818:Animals; D052160:Benzothiazoles / Q000378:metabolism; D001713:Biphenyl Compounds / Q000378:metabolism; D001786:Blood Glucose / Q000378:metabolism; D017301:Ca(2+) Mg(2+)-ATPase / Q000378:metabolism; D000252:Calcium-Transporting ATPases / Q000378:metabolism; D004347:Drug Interactions; D044950:Flavanones / Q000494:pharmacology*; D016166:Free Radical Scavengers / Q000494:pharmacology; D005916:Globulins / Q000378:metabolism; D006023:Glycoproteins / Q000097:blood / Q000378:metabolism; D006834:Hydrazines / Q000378:metabolism; D007501:Iron / Q000097:blood / Q000378:metabolism; D007545:Isoproterenol / Q000037:antagonists & inhibitors / Q000633:toxicity*; D008297:Male; D009203:Myocardial Infarction / Q000097:blood / Q000139:chemically induced* / Q000378:metabolism / Q000517:prevention & control*; D009569:Nitric Oxide / Q000378:metabolism; D009929:Organ Size / Q000187:drug effects; D010851:Picrates; D051381:Rats; D017208:Rats, Wistar; D012709:Serum Albumin / Q000378:metabolism; D000254:Sodium-Potassium-Exchanging ATPase / Q000378:metabolism; D013451:Sulfonic Acids / Q000378:metabolism; D014527:Uric Acid / Q000097:blood / Q000378:metabolism
D052160:Benzothiazoles; D001713:Biphenyl Compounds; D001786:Blood Glucose; D044950:Flavanones; D016166:Free Radical Scavengers; D005916:Globulins; D006023:Glycoproteins; D006834:Hydrazines; D010851:Picrates; D012709:Serum Albumin; D013451:Sulfonic Acids; D014527:Uric Acid; C002502:2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid; D009569:Nitric Oxide; C004931:1,1-diphenyl-2-picrylhydrazyl; D007501:Iron; D017301:Ca(2+) Mg(2+)-ATPase; D000252:Calcium-Transporting ATPases; D000254:Sodium-Potassium-Exchanging ATPase; D007545:Isoproterenol; C005274:naringin